Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 2000

View Archived Issues

Synsorb Pk receives fast track designation from FDA for prevention of HUS

Enrollment in Altropane PD diagnosis trial now complete

InSite Vision's batimastat eyedrops show antiangiogenic activity

Decitabine effective in myelodysplastic syndrome

Visudyne T-IND program expanded

Medicure's MC-1 shows good results in ischemia models

More good news about Enbrel: NEJM article describes efficacy in juvenile RA

NeoPharm receives milestone payment from P&U for LEP

FDA grants priority review for new once-daily Videx capsules

Calcilytic compounds described by SB for use in disorders of bone or mineral homeostasis

ODAC does not recommend approval of oxaliplatin combination therapy

Novartis discloses new antiangiogenic agents acting on growth factor-mediated signal transmission

Medivir reinitiates development of alovudine for AIDS

New 9-aminocamptothecins endowed with potent antitumor activity

Subtype-selective PDE4 inhibitors claimed by Pfizer for respiratory and other disorders

Phase II results positive for Medivir's shingles antiviral

AstraZeneca pipeline includes novel chemokine receptor modulators

Abbott's new alpha1A-adrenoceptor agonists, their preparation, activity and use

Whole genome sequencing of N. meningitidis leads to novel vaccine candidates

German launch for Mifegyne announced

FDA advisory committee recommends approval of Camptosar as first-line therapy of colorectal cancer

New PDT candidate designed by Chinese university researchers

Memory-enhancing effects of huperzine tablets and capsules proven equivalent

Cariporide: no improvement in myocardial stunning/infarct size in GUARDIAN trial subgroup

TxA2 antagonist from Bayer may have potential in atherosclerosis according to ACC presentation

First human data reported for GI-262570 at recent scientific forum

Licensing opportunity from Vita-Invest: fixed-dose antihypertensive combination

Potential for drug interactions of Sch-58235 evaluated in humans

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...